Glucocorticoid-Induced Ocular Hypertension and Glaucoma

References

• Sun Y, Chen A, Zou M, et al. Time trends, associations and prevalence of blindness and vision loss due to glaucoma: an analysis of observational data from the Global Burden of Disease Study 2017. BMJ Open. 2022;12(1):e053805. doi:10.1136/bmjopen-2021-053805
   PubMed Web of Science ®Google Scholar
• Thorne GW, Forsham PH, Frawley TF, et al. The clinical usefulness of ACTH and cortisone. N Engl J Med. 1950;242(21):824–834. doi:10.1056/NEJM195005252422105
   PubMed Web of Science ®Google Scholar
• F J. Cortisone et tension ocularire. Ann Ocul. 1954;187:805–816.
   PubMedGoogle Scholar
• Covell LL. Glaucoma Induced by Systemic Steroid Therapy. Am J Ophthalmol. 1958;45(1):108–109. doi:10.1016/0002-9394(58)91403-X
   PubMed Web of Science ®Google Scholar
• Armaly MF. EFFECT OF CORTICOSTEROIDS ON INTRAOCULAR PRESSURE AND FLUID DYNAMICS. I. Arch Ophthalmol Chic. 1963;70:482–491. doi:10.1001/archopht.1963.00960050484010
   PubMed Web of Science ®Google Scholar
• Becker B, Mills DW. Corticosteroids and Intraocular Pressure. Arch Ophthalmol. 1963;70(4):500–507. doi:10.1001/archopht.1963.00960050502012
   PubMedGoogle Scholar
• Llobet A, Gasull X, Gual A. Understanding Trabecular Meshwork Physiology: a Key to the Control of Intraocular Pressure? Physiology. 2003;18(5):205–209. doi:10.1152/nips.01443.2003
   Google Scholar
• Kitazawa Y, Horie T. The Prognosis of Corticosteroid-Responsive Individuals. Arch Ophthalmol. 1981;99(5):819–823. doi:10.1001/archopht.1981.03930010819005
   PubMedGoogle Scholar
• Lewis JM, Priddy T, Judd J, et al. Intraocular Pressure Response to Topical Dexamethasone as a Predictor for the Development of Primary Open-Angle Glaucoma. Am J Ophthalmol. 1988;106(5):607–612. doi:10.1016/0002-9394(88)90595-8
   PubMed Web of Science ®Google Scholar
• Bill A. Blood circulation and fluid dynamics in the eye. Physiol Rev. 1975;55(3):383–417. doi:10.1152/physrev.1975.55.3.383
   PubMed Web of Science ®Google Scholar
• Stamer WD, Clark AF. The many faces of the trabecular meshwork cell. Exp Eye Res. 2017;158:112–123. doi:10.1016/j.exer.2016.07.009
   PubMed Web of Science ®Google Scholar
• Stamer WD, Braakman ST, Zhou EH, et al. Biomechanics of Schlemm’s canal endothelium and intraocular pressure reduction. Prog Retin Eye Res. 2015;44:86–98. doi:10.1016/j.preteyeres.2014.08.002
   PubMed Web of Science ®Google Scholar
• Ethier CR, Coloma FM, Sit AJ, Johnson M. Two Pore Types in the Inner-Wall Endothelium of Schlemm’s Canal. Ophthalmol Vis. 1998;39(11):2041.
   PubMed Web of Science ®Google Scholar
• Mäepea O, Bill A. The pressures in the episcleral veins, Schlemm’s canal and the trabecular meshwork in monkeys: effects of changes in intraocular pressure. Exp Eye Res. 1989;49(4):645–663. doi:10.1016/S0014-4835(89)80060-0
   PubMed Web of Science ®Google Scholar
• Overby DR, Stamer WD, Johnson M. The changing paradigm of outflow resistance generation: towards synergistic models of the JCT and inner wall endothelium. Exp Eye Res. 2009;88(4):656–670. doi:10.1016/j.exer.2008.11.033
   PubMed Web of Science ®Google Scholar
• Encío IJ, Detera-Wadleigh SD. The genomic structure of the human glucocorticoid receptor. J Biol Chem. 1991;266(11):7182–7188.
   PubMed Web of Science ®Google Scholar
• Wordinger RJ, Clark AF. Effects of glucocorticoids on the trabecular meshwork: towards a better understanding of glaucoma. Prog Retin Eye Res. 1999;18(5):629–667. doi:10.1016/S1350-9462(98)00035-4
   PubMed Web of Science ®Google Scholar
• Wang RYR, Noddings CM, Kirschke E, Myasnikov AG, Johnson JL, Agard DA. Structure of Hsp90−Hsp70−Hop−GR reveals the Hsp90 client-loading mechanism. Nature. 2022;601(7893):460–464. doi:10.1038/s41586-021-04252-1
   PubMed Web of Science ®Google Scholar
• Cox MB, Johnson JL. The Role of p23, Hop, Immunophilins, and Other Co-chaperones in Regulating Hsp90 Function. In: Calderwood SK, Prince TL editors. Molecular Chaperones: Methods and Protocols. Methods in Molecular Biology. Humana Press; 2011:45–66. doi:10.1007/978-1-61779-295-3_4
   Google Scholar
• Smith DF, Toft DO. Minireview: the Intersection of Steroid Receptors with Molecular Chaperones: observations and Questions. Mol Endocrinol. 2008;22(10):2229–2240. doi:10.1210/me.2008-0089
   PubMedGoogle Scholar
• Zhang X, Clark AF, Yorio T. Heat Shock Protein 90 Is an Essential Molecular Chaperone for Nuclear Transport of Glucocorticoid Receptor β. Invest Ophthalmol Vis Sci. 2006;47(2):700–708. doi:10.1167/iovs.05-0697
   PubMed Web of Science ®Google Scholar
• Zhang X, Clark AF, Yorio T. FK506-Binding Protein 51 Regulates Nuclear Transport of the Glucocorticoid Receptor β and Glucocorticoid Responsiveness. Invest Ophthalmol Vis Sci. 2008;49(3):1037–1047. doi:10.1167/iovs.07-1279
   PubMed Web of Science ®Google Scholar
• Patel GC, Millar JC, Clark AF. Glucocorticoid Receptor Transactivation Is Required for Glucocorticoid-Induced Ocular Hypertension and Glaucoma. Invest Ophthalmol Vis Sci. 2019;60(6):1967–1978. doi:10.1167/iovs.18-26383
   PubMed Web of Science ®Google Scholar
• Bledsoe RK, Montana VG, Stanley TB, et al. Crystal Structure of the Glucocorticoid Receptor Ligand Binding Domain Reveals a Novel Mode of Receptor Dimerization and Coactivator Recognition. Cell. 2002;110(1):93–105. doi:10.1016/S0092-8674(02)00817-6
   PubMed Web of Science ®Google Scholar
• Caamaño CA, Morano MI, Dalman FC, Pratt WB, Akil H. A Conserved Proline in the hsp90 Binding Region of the Glucocorticoid Receptor Is Required for hsp90 Heterocomplex Stabilization and Receptor Signaling*. J Biol Chem. 1998;273(32):20473–20480. doi:10.1074/jbc.273.32.20473
   PubMed Web of Science ®Google Scholar
• Reichardt HM, Kaestner KH, Tuckermann J, et al. DNA Binding of the Glucocorticoid Receptor Is Not Essential for Survival. Cell. 1998;93(4):531–541. doi:10.1016/S0092-8674(00)81183-6
   PubMed Web of Science ®Google Scholar
• Sundahl N, Bridelance J, Libert C, De Bosscher K, Beck IM. Selective glucocorticoid receptor modulation: new directions with non-steroidal scaffolds. Pharmacol Ther. 2015;152:28–41. doi:10.1016/j.pharmthera.2015.05.001
   PubMed Web of Science ®Google Scholar
• Hübner S, Dejager L, Libert C, Tuckermann JP. The glucocorticoid receptor in inflammatory processes: transrepression is not enough. Biol Chem. 2015;396(11):1223–1231. doi:10.1515/hsz-2015-0106
   PubMed Web of Science ®Google Scholar
• Jain A, Wordinger RJ, Yorio T, Clark AF. Role of the alternatively spliced glucocorticoid receptor isoform GRβ in steroid responsiveness and glaucoma. J Ocul Pharmacol Ther off J Assoc Ocul Pharmacol Ther. 2014;30(2–3):121–127. doi:10.1089/jop.2013.0239
   PubMed Web of Science ®Google Scholar
• Zhang X, Clark AF, Yorio T. Regulation of Glucocorticoid Responsiveness in Glaucomatous Trabecular Meshwork Cells by Glucocorticoid Receptor-β. Invest Ophthalmol Vis Sci. 2005;46(12):4607–4616. doi:10.1167/iovs.05-0571
   PubMed Web of Science ®Google Scholar
• Roberti G, Oddone F, Agnifili L, et al. Steroid-induced glaucoma: epidemiology, pathophysiology, and clinical management. Surv Ophthalmol. 2020;65(4):458–472. doi:10.1016/j.survophthal.2020.01.002
   PubMed Web of Science ®Google Scholar
• Zhang X, Ognibene CM, Clark AF, Yorio T. Dexamethasone inhibition of trabecular meshwork cell phagocytosis and its modulation by glucocorticoid receptor β. Exp Eye Res. 2007;84(2):275–284. doi:10.1016/j.exer.2006.09.022
   PubMed Web of Science ®Google Scholar
• Patel GC, Liu Y, Millar JC, Clark AF. Glucocorticoid receptor GRβ regulates glucocorticoid-induced ocular hypertension in mice. Sci Rep. 2018;8:862. doi:10.1038/s41598-018-19262-9
   PubMed Web of Science ®Google Scholar
• Cuzzoni E, De Iudicibus S, Bartoli F, Ventura A, Decorti G. Association between BclI polymorphism in the NR3C1 gene and in vitro individual variations in lymphocyte responses to methylprednisolone. Br J Clin Pharmacol. 2012;73(4):651–655. doi:10.1111/j.1365-2125.2011.04130.x
   PubMed Web of Science ®Google Scholar
• Fingert JH, Alward WL, Wang K, Yorio T, Clark AF. Assessment of SNPs associated with the human glucocorticoid receptor in primary open-angle glaucoma and steroid responders. Mol Vis. 2010;16:596–601.
   PubMed Web of Science ®Google Scholar
• Gerzenstein SM, Pletcher MT, Cervino ACL, et al. Glucocorticoid Receptor Polymorphisms and Intraocular Pressure Response to Intravitreal Triamcinolone Acetonide. Ophthalmic Genet. 2008;29(4):166–170. doi:10.1080/13816810802320217
   PubMed Web of Science ®Google Scholar
• Iudicibus SD, Stocco G, Martelossi S, et al. Genetic predictors of glucocorticoid response in pediatric patients with inflammatory bowel diseases. J Clin Gastroenterol. 2011;45(1). doi:10.1097/MCG.0b013e3181e8ae93
   PubMed Web of Science ®Google Scholar
• Jain A, Wordinger RJ, Yorio T, Clark AF. Spliceosome Protein (SRp) Regulation of Glucocorticoid Receptor Isoforms and Glucocorticoid Response in Human Trabecular Meshwork Cells. Invest Ophthalmol Vis Sci. 2012;53(2):857–866. doi:10.1167/iovs.11-8497
   PubMed Web of Science ®Google Scholar
• Jain A, Liu X, Wordinger RJ, Yorio T, Cheng YQ, Clark AF. Effects of Thailanstatins on Glucocorticoid Response in Trabecular Meshwork and Steroid-Induced Glaucoma. Invest Ophthalmol Vis Sci. 2013;54(5):3137–3142. doi:10.1167/iovs.12-11480
   PubMed Web of Science ®Google Scholar
• Wang XQ, Duan ZX, He XG, Zhou XY. Clinical relevance of the glucocorticoid receptor gene polymorphisms in glucocorticoid−induced ocular hypertension and primary open angle glaucoma. Int J Ophthalmol. 2015;8(1):169–173. doi:10.3980/j.issn.2222-3959.2015.01.30
   PubMed Web of Science ®Google Scholar
• Will CL, Lührmann R. Spliceosome Structure and Function. Cold Spring Harb Perspect Biol. 2011;3(7):a003707. doi:10.1101/cshperspect.a003707
   PubMed Web of Science ®Google Scholar
• Trapp T, Holsboer F. Nuclear Orphan Receptor as a Repressor of Glucocorticoid Receptor Transcriptional Activity (*). J Biol Chem. 1996;271(17):9879–9882. doi:10.1074/jbc.271.17.9879
   PubMed Web of Science ®Google Scholar
• Kralli A, Bohen SP, Yamamoto KR. LEM1, an ATP-binding-cassette transporter, selectively modulates the biological potency of steroid hormones. Proc Natl Acad Sci. 1995;92(10):4701–4705. doi:10.1073/pnas.92.10.4701
   PubMed Web of Science ®Google Scholar
• Liu H, Yang ZK, Li Y, Zhang WJ, Wang YT, Duan XC. ABCB1 variants confer susceptibility to primary open-angle glaucoma and predict individual differences to latanoprost treatment. Biomed Pharmacother. 2016;80:115–120. doi:10.1016/j.biopha.2016.02.028
   PubMed Web of Science ®Google Scholar
• Becker B, Hahn KA. Topical Corticosteroids and Heredity in Primary Open-Angle Glaucoma*. Am J Ophthalmol. 1964;57(4):543–551. doi:10.1016/0002-9394(64)92500-0
   PubMed Web of Science ®Google Scholar
• Bermudez JY, Webber HC, Brown B, Braun TA, Clark AF, Mao W. A Comparison of Gene Expression Profiles between Glucocorticoid Responder and Non-Responder Bovine Trabecular Meshwork Cells Using RNA Sequencing. PLoS One. 2017;12(1):e0169671. doi:10.1371/journal.pone.0169671
   PubMed Web of Science ®Google Scholar
• Rauz S, Walker EA, Shackleton CHL, Hewison M, Murray PI, Stewart PM. Expression and Putative Role of 11β-Hydroxysteroid Dehydrogenase Isozymes within the Human Eye. Invest Ophthalmol Vis Sci. 2001;42(9):2037–2042.
   PubMed Web of Science ®Google Scholar
• McCarty GR, Schwartz B. Increased plasma noncortisol glucocorticoid activity in open-angle glaucoma. Invest Ophthalmol Vis Sci. 1991;32(5):1600–1608.
   PubMed Web of Science ®Google Scholar
• Ray S, Mehra KS, Misra S, Singh R. Plasma cortisol in glaucoma. Ann Ophthalmol. 1977;9(9):1151–1154.
   PubMedGoogle Scholar
• Rozsíval P, Hampl R, Obenberger J, Stárka L, Rehák S. Aqueous humour and plasma cortisol levels in glaucoma and cataract patients. Curr Eye Res. 1981;1(7):391–396. doi:10.3109/02713688109019976
   PubMed Web of Science ®Google Scholar
• Schwartz B, McCarty G, Rosner B. Increased plasma free cortisol in ocular hypertension and open angle glaucoma. Arch Ophthalmol Chic IL 1960. 1987;105(8):1060–1065. doi:10.1001/archopht.1987.01060080062029
   PubMedGoogle Scholar
• Schwartz B, Seddon JM. Increased plasma cortisol levels in ocular hypertension. Arch Ophthalmol Chic IL 1960. 1981;99(10):1791–1794. doi:10.1001/archopht.1981.03930020665008
   PubMedGoogle Scholar
• Choi KJ, Na YJ, Park SB, Jung WH, Sung HR, Kim KY. Carbenoxolone prevents chemical eye ischemia-reperfusion-induced cell death via 11β-hydroxysteroid dehydrogenase type 1 inhibition. Pharmacol Res. 2017;123:62–72. doi:10.1016/j.phrs.2017.07.002
   PubMed Web of Science ®Google Scholar
• Choi KJ, Na YJ, Jung WH, et al. Protective effect of a novel selective 11β-HSD1 inhibitor on eye ischemia-reperfusion induced glaucoma. Biochem Pharmacol. 2019;169:113632. doi:10.1016/j.bcp.2019.113632
   PubMed Web of Science ®Google Scholar
• Piccolo S, Dupont S, Cordenonsi M. The Biology of YAP/TAZ: hippo Signaling and Beyond. Physiol Rev. 2014;94(4):1287–1312. doi:10.1152/physrev.00005.2014
   PubMed Web of Science ®Google Scholar
• Totaro A, Panciera T, Piccolo S. YAP/TAZ upstream signals and downstream responses. Nat Cell Biol. 2018;20(8):888–899. doi:10.1038/s41556-018-0142-z
   PubMed Web of Science ®Google Scholar
• Ruggeri N REGULATION OF YAP BY GLUCOCORTICOIDS. Doctoral Thesis. Università degli studi di Trieste; 2015. Available from: https://www.openstarts.units.it/handle/10077/11122. Accessed May 10, 2023.
   Google Scholar
• Sorrentino G, Ruggeri N, Zannini A, et al. Glucocorticoid receptor signalling activates YAP in breast cancer. Nat Commun. 2017;8:14073. doi:10.1038/ncomms14073
   PubMed Web of Science ®Google Scholar
• Harvey KF, Pfleger CM, Hariharan IK. The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell. 2003;114(4):457–467. doi:10.1016/s0092-8674(03)00557-9
   PubMed Web of Science ®Google Scholar
• Jia J, Zhang W, Wang B, Trinko R, Jiang J. The Drosophila Ste20 family kinase dMST functions as a tumor suppressor by restricting cell proliferation and promoting apoptosis. Genes Dev. 2003;17(20):2514–2519. doi:10.1101/gad.1134003
   PubMed Web of Science ®Google Scholar
• Pantalacci S, Tapon N, Léopold P. The Salvador partner Hippo promotes apoptosis and cell-cycle exit in Drosophila. Nat Cell Biol. 2003;5(10):921–927. doi:10.1038/ncb1051
   PubMed Web of Science ®Google Scholar
• Udan RS, Kango-Singh M, Nolo R, Tao C, Halder G. Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway. Nat Cell Biol. 2003;5(10):914–920. doi:10.1038/ncb1050
   PubMed Web of Science ®Google Scholar
• Wu S, Huang J, Dong J, Pan D. hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell. 2003;114(4):445–456. doi:10.1016/s0092-8674(03)00549-x
   PubMed Web of Science ®Google Scholar
• Ibar C, Kirichenko E, Keepers B, Enners E, Fleisch K, Irvine KD. Tension-dependent regulation of mammalian Hippo signaling through LIMD1. J Cell Sci. 2018;131(5):jcs214700. doi:10.1242/jcs.214700
   PubMed Web of Science ®Google Scholar
• Nakamura R, Bing R, Doyle CP, Garabedian MJ, Branski RC. Glucocorticoids activate Yes-associated protein in human vocal fold fibroblasts. Exp Cell Res. 2021;405(2):112681. doi:10.1016/j.yexcr.2021.112681
   PubMed Web of Science ®Google Scholar
• Xu S, Liu Y, Hu R, et al. TAZ inhibits GR and coordinates hepatic glucose homeostasis in normal physiologic states. eLife. 2020:e57462. doi:10.1101/2020.05.12.091264
   Web of Science ®Google Scholar
• Murphy R, Irnaten M, Hopkins A, et al. Matrix Mechanotransduction via Yes-Associated Protein in Human Lamina Cribrosa Cells in Glaucoma. Invest Ophthalmol Vis Sci. 2022;63(1):16. doi:10.1167/iovs.63.1.16
   PubMed Web of Science ®Google Scholar
• Gu X, Ge L, Ren B, et al. Glucocorticoids Promote Extracellular Matrix Component Remodeling by Activating YAP in Human Retinal Capillary Endothelial Cells. Front Cell Dev Biol. 2021;9. doi:10.3389/fcell.2021.738341
   Web of Science ®Google Scholar
• Li H, Raghunathan V, Stamer WD, Ganapathy PS, Herberg S. Extracellular Matrix Stiffness and TGFβ2 Regulate YAP/TAZ Activity in Human Trabecular Meshwork Cells. Front Cell Dev Biol. 2022;10: 844342.
   PubMed Web of Science ®Google Scholar
• Liu Z, Li S, Qian X, Li L, Zhang H, Liu Z. RhoA/ROCK-YAP/TAZ Axis Regulates the Fibrotic Activity in Dexamethasone-Treated Human Trabecular Meshwork Cells. Front Mol Biosci. 2021;8: 728514.
   Web of Science ®Google Scholar
• Yoo H, Singh A, Li H, et al. Simvastatin Attenuates Glucocorticoid-Induced Human Trabecular Meshwork Cell Dysfunction via YAP/TAZ Inactivation. Curr Eye Res. 2023;1(2):1–14. doi:10.1080/02713683.2023.2206067
   Google Scholar
• Logan CY, Nusse R. The Wnt Signaling Pathway in Development and Disease. Annu Rev Cell Dev Biol. 2004;20(1):781–810. doi:10.1146/annurev.cellbio.20.010403.113126
   PubMedGoogle Scholar
• Clevers H. Wnt/β-Catenin Signaling in Development and Disease. Cell. 2006;127(3):469–480. doi:10.1016/j.cell.2006.10.018
   PubMed Web of Science ®Google Scholar
• Sugali CK, Rayana NP, Dai J, et al. The Canonical Wnt Signaling Pathway Inhibits the Glucocorticoid Receptor Signaling Pathway in the Trabecular Meshwork. Am J Pathol. 2021;191(6):1020–1035. doi:10.1016/j.ajpath.2021.02.018
   PubMed Web of Science ®Google Scholar
• Webber HC, Bermudez JY, Millar JC, Mao W, Clark AF. The Role of Wnt/β-Catenin Signaling and K-Cadherin in the Regulation of Intraocular Pressure. Invest Ophthalmol Vis Sci. 2018;59(3):1454–1466. doi:10.1167/iovs.17-21964
   PubMed Web of Science ®Google Scholar
• Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell. 1982;31(1):99–109. doi:10.1016/0092-8674(82)90409-3
   PubMed Web of Science ®Google Scholar
• Sharma RP, Chopra VL. Effect of the wingless (wg1) mutation on wing and haltere development in Drosophila melanogaster. Dev Biol. 1976;48(2):461–465. doi:10.1016/0012-1606(76)90108-1
   PubMed Web of Science ®Google Scholar
• Nusse R, Brown A, Papkoff J, et al. A new nomenclature for int-1 and related genes: the Wnt gene family. Cell. 1991;64(2):231. doi:10.1016/0092-8674(91)90633-A
   PubMed Web of Science ®Google Scholar
• Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis. 2008;4(2):68–75.
   PubMedGoogle Scholar
• He X, Semenov M, Tamai K, Zeng X. LDL receptor-related proteins 5 and 6 in Wnt/β-catenin signaling:Arrows point the way. Development. 2004;131(8):1663–1677. doi:10.1242/dev.01117
   PubMed Web of Science ®Google Scholar
• MacDonald BT, Tamai K, He X. Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17(1):9–26. doi:10.1016/j.devcel.2009.06.016
   PubMed Web of Science ®Google Scholar
• Wang WH, McNatt LG, Pang IH, et al. Increased expression of the WNT antagonist sFRP-1 in glaucoma elevates intraocular pressure. J Clin Invest. 2008;118(3):1056–1064. doi:10.1172/JCI33871
   PubMed Web of Science ®Google Scholar
• Mao W, Liu Y, Mody A, Montecchi-Palmer M, Wordinger RJ, Clark AF. Characterization of a spontaneously immortalized bovine trabecular meshwork cell line. Exp Eye Res. 2012;105:53–59. doi:10.1016/j.exer.2012.10.007
   PubMed Web of Science ®Google Scholar
• Raghunathan VK, Morgan JT, Park SA, et al. Dexamethasone Stiffens Trabecular Meshwork, Trabecular Meshwork Cells, and Matrix. Invest Ophthalmol Vis Sci. 2015;56(8):4447–4459. doi:10.1167/iovs.15-16739
   PubMed Web of Science ®Google Scholar
• Yuan Y, Call MK, Yuan Y, et al. Dexamethasone Induces Cross-Linked Actin Networks in Trabecular Meshwork Cells Through Noncanonical Wnt Signaling. Invest Ophthalmol Vis Sci. 2013;54(10):6502–6509. doi:10.1167/iovs.13-12447
   PubMed Web of Science ®Google Scholar
• Maddala R, Eldawy C, Bachman W, Soderblom EJ, Rao PV. Glypican-4 regulated actin cytoskeletal reorganization in glucocorticoid treated trabecular meshwork cells and involvement of Wnt/PCP signaling. J Cell Physiol. 2023;238(3):631–646. doi:10.1002/jcp.30953
   PubMed Web of Science ®Google Scholar
• Barrett CSX, Millena AC, Khan SA. TGF-β Effects on Prostate Cancer Cell Migration and Invasion Require FosB. Prostate. 2017;77(1):72–81. doi:10.1002/pros.23250
   PubMed Web of Science ®Google Scholar
• Clark DA, Coker R. Transforming growth factor-beta (TGF-beta). Int J Biochem Cell Biol. 1998;30(3):293–298. doi:10.1016/s1357-2725(97)00128-3
   PubMed Web of Science ®Google Scholar
• Duenker N. Transforming growth factor-beta (TGF-beta) and programmed cell death in the vertebrate retina. Int Rev Cytol. 2005;245:17–43. doi:10.1016/S0074-7696(05)45002-0
   PubMedGoogle Scholar
• Gao T, Cao Y, Hu M, Du Y. The activation of TGF-β signaling promotes cell migration and invasion of ectopic endometrium by targeting NRP2. Reprod Biol. 2022;22(4):100697. doi:10.1016/j.repbio.2022.100697
   PubMed Web of Science ®Google Scholar
• Zhang Y, Alexander PB, Wang XF. TGF-β Family Signaling in the Control of Cell Proliferation and Survival. Cold Spring Harb Perspect Biol. 2017;9(4):a022145. doi:10.1101/cshperspect.a022145
   PubMed Web of Science ®Google Scholar
• Lawrence DA. Transforming growth factor-beta: a general review. Eur Cytokine Netw. 1996;7(3):363–374.
   PubMed Web of Science ®Google Scholar
• Itoh S, Itoh F, Goumans MJ, ten Dijke P. Signaling of transforming growth factor-β family members through Smad proteins. Eur J Biochem. 2000;267(24):6954–6967. doi:10.1046/j.1432-1327.2000.01828.x
   PubMedGoogle Scholar
• Tripathi RC, Li J, Chan WF, Tripathi BJ. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp Eye Res. 1994;59(6):723–727. doi:10.1006/exer.1994.1158
   PubMed Web of Science ®Google Scholar
• Wordinger RJ, Sharma T, Clark AF. The Role of TGF-β2 and Bone Morphogenetic Proteins in the Trabecular Meshwork and Glaucoma. J Ocul Pharmacol Ther. 2014;30(2–3):154–162. doi:10.1089/jop.2013.0220
   PubMed Web of Science ®Google Scholar
• Gottanka J, Chan D, Eichhorn M, Lütjen-Drecoll E, Ethier CR. Effects of TGF-beta2 in perfused human eyes. Invest Ophthalmol Vis Sci. 2004;45(1):153–158. doi:10.1167/iovs.03-0796
   PubMed Web of Science ®Google Scholar
• Montecchi-Palmer M, Bermudez JY, Webber HC, Patel GC, Clark AF, Mao W. TGFβ2 Induces the Formation of Cross-Linked Actin Networks (CLANs) in Human Trabecular Meshwork Cells Through the Smad and Non-Smad Dependent Pathways. Invest Ophthalmol Vis Sci. 2017;58(2):1288–1295. doi:10.1167/iovs.16-19672
   PubMed Web of Science ®Google Scholar
• Robertson JV, Golesic E, Gauldie J, West-Mays JA. Ocular Gene Transfer of Active TGF-β Induces Changes in Anterior Segment Morphology and Elevated IOP in Rats. Invest Ophthalmol Vis Sci. 2010;51(1):308–318. doi:10.1167/iovs.09-3380
   PubMed Web of Science ®Google Scholar
• Uemura T, Sakai O, Sakamoto Y. Transgenic mice expressing Transforming growth factor-β2 increased intraocular pressure. Invest Ophthalmol Vis Sci. 2019;60(9):3773.
   Web of Science ®Google Scholar
• Kasetti RB, Maddineni P, Patel PD, Searby C, Sheffield VC, Zode GS. Transforming growth factor β2 (TGFβ2) signaling plays a key role in glucocorticoid-induced ocular hypertension. J Biol Chem. 2018;293(25):9854–9868. doi:10.1074/jbc.RA118.002540
   PubMed Web of Science ®Google Scholar
• Clark AF, Wilson K, McCartney MD, Miggans ST, Kunkle M, Howe W. Glucocorticoid-induced formation of cross-linked actin networks in cultured human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 1994;35(1):281–294.
   PubMed Web of Science ®Google Scholar
• Bermudez JY, Webber HC. Two-Dimensional Differential In-Gel Electrophoresis (2D-DIGE) Reveals Proteins Associated with Cross-Linked Actin Networks in Human Trabecular Meshwork Cells. J Clin Exp Ophthalmol. 2016;07(04). doi:10.4172/2155-9570.1000584
   Google Scholar
• Filla MS, Woods A, Kaufman PL, Peters DM. Beta1 and beta3 integrins cooperate to induce syndecan-4-containing cross-linked actin networks in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2006;47(5):1956–1967. doi:10.1167/iovs.05-0626
   PubMed Web of Science ®Google Scholar
• Filla MS, Schwinn K, Sheibani M. Distinct β1 and β3 integrin pathways converge to regulate cross-linked actin network (CLAN) formation in human trabecular meshwork (HTM) cells. Invest Ophthalmol Vis Sci. 2009;50(12):5723–5731. doi:10.1167/iovs.08-3215
   PubMed Web of Science ®Google Scholar
• Bermudez JY, Montecchi-Palmer M, Mao W, Clark AF. Cross-linked actin networks (CLANs) in glaucoma. Exp Eye Res. 2017;159:16–22. doi:10.1016/j.exer.2017.02.010
   PubMed Web of Science ®Google Scholar
• Wilson K, McCartney MD, Miggans ST, Clark AF. Dexamethasone induced ultrastructural changes in cultured human trabecular meshwork cells. Curr Eye Res. 1993;12(9):783–793. doi:10.3109/02713689309020383
   PubMed Web of Science ®Google Scholar
• Clark AF, Lane D, Wilson K, Miggans ST, McCartney MD. Inhibition of dexamethasone-induced cytoskeletal changes in cultured human trabecular meshwork cells by tetrahydrocortisol. Invest Ophthalmol Vis Sci. 1996;37(5):805–813.
   PubMed Web of Science ®Google Scholar
• O’Reilly S, Pollock N, Currie L, Paraoan L, Clark AF, Grierson I. Inducers of Cross-Linked Actin Networks in Trabecular Meshwork Cells. Invest Ophthalmol Vis Sci. 2011;52(10):7316–7324. doi:10.1167/iovs.10-6692
   PubMed Web of Science ®Google Scholar
• Wade NC, Grierson I, O’Reilly S, et al. Cross-linked actin networks (CLANs) in bovine trabecular meshwork cells. Exp Eye Res. 2009;89(5):648–659. doi:10.1016/j.exer.2009.06.006
   PubMed Web of Science ®Google Scholar
• Mao W, Liu Y, Wordinger RJ, Clark AF. A Magnetic Bead-Based Method for Mouse Trabecular Meshwork Cell Isolation. Invest Ophthalmol Vis Sci. 2013;54(5):3600–3606. doi:10.1167/iovs.13-12033
   PubMed Web of Science ®Google Scholar
• Clark R, Nosie A, Walker T, et al. Comparative Genomic and Proteomic Analysis of Cytoskeletal Changes in Dexamethasone-Treated Trabecular Meshwork Cells. Mol Cell Proteomics MCP. 2013;12(1):194–206. doi:10.1074/mcp.M112.019745
   PubMed Web of Science ®Google Scholar
• Filla MS, Schwinn MK, Nosie AK, Clark RW, Peters DM. Dexamethasone-Associated Cross-Linked Actin Network Formation in Human Trabecular Meshwork Cells Involves β3 Integrin Signaling. Invest Ophthalmol Vis Sci. 2011;52(6):2952–2959. doi:10.1167/iovs.10-6618
   PubMed Web of Science ®Google Scholar
• Peng M, Rayana NP, Dai J, et al. Cross-linked actin networks (CLANs) affect stiffness and/or actin dynamics in transgenic transformed and primary human trabecular meshwork cells. Exp Eye Res. 2022;220:109097. doi:10.1016/j.exer.2022.109097
   PubMed Web of Science ®Google Scholar
• Fujimoto T, Inoue T, Kameda T, et al. Involvement of RhoA/Rho-associated kinase signal transduction pathway in dexamethasone-induced alterations in aqueous outflow. Invest Ophthalmol Vis Sci. 2012;53(11):7097–7108. doi:10.1167/iovs.12-9989
   PubMed Web of Science ®Google Scholar
• Wang K, Read AT, Sulchek T, Ethier CR. Trabecular meshwork stiffness in glaucoma. Exp Eye Res. 2017;158:3–12. doi:10.1016/j.exer.2016.07.011
   PubMed Web of Science ®Google Scholar
• Raghunathan VK, Benoit J, Kasetti R, et al. Glaucomatous cell derived matrices differentially modulate non-glaucomatous trabecular meshwork cellular behavior. Acta Biomater. 2018;71:444–459. doi:10.1016/j.actbio.2018.02.037
   PubMed Web of Science ®Google Scholar
• Last JA, Pan T, Ding Y, et al. Elastic modulus determination of normal and glaucomatous human trabecular meshwork. Invest Ophthalmol Vis Sci. 2011;52(5):2147–2152. doi:10.1167/iovs.10-6342
   PubMed Web of Science ®Google Scholar
• Sherwood JM, Stamer WD, Overby DR. A model of the oscillatory mechanical forces in the conventional outflow pathway. J R Soc Interface. 2019;16(150):20180652. doi:10.1098/rsif.2018.0652
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Johnson DH. Dexamethasone decreases phagocytosis by human trabecular meshwork cells in situ. Invest Ophthalmol Vis Sci. 1997;38(9):1902–1907.
   PubMed Web of Science ®Google Scholar
• Zode GS, Sharma AB, Lin X, et al. Ocular-specific ER stress reduction rescues glaucoma in murine glucocorticoid-induced glaucoma. J Clin Invest. 2014;124(5):1956–1965. doi:10.1172/JCI69774
   PubMed Web of Science ®Google Scholar
• Faralli JA, Gagen D, Filla MS, Crotti TN, Peters DM. Dexamethasone increases αvβ3 integrin expression and affinity through a calcineurin/NFAT pathway. Biochim Biophys Acta. 2013;1833(12):3306–3313. doi:10.1016/j.bbamcr.2013.09.020
   PubMed Web of Science ®Google Scholar
• Gagen D, Faralli JA, Filla MS, Peters DM. The role of integrins in the trabecular meshwork. J Ocul Pharmacol Ther off J Assoc Ocul Pharmacol Ther. 2014;30(2–3):110–120. doi:10.1089/jop.2013.0176
   PubMed Web of Science ®Google Scholar
• Filla MS, Schwinn MK, Sheibani N, Kaufman PL, Peters DM. Regulation of cross-linked actin network (CLAN) formation in human trabecular meshwork (HTM) cells by convergence of distinct beta1 and beta3 integrin pathways. Invest Ophthalmol Vis Sci. 2009;50(12):5723–5731. doi:10.1167/iovs.08-3215
   PubMed Web of Science ®Google Scholar
• Gagen D, Filla MS, Clark R, Liton P, Peters DM. Activated αvβ3 integrin regulates αvβ5 integrin-mediated phagocytosis in trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2013;54(7):5000–5011. doi:10.1167/iovs.13-12084
   PubMed Web of Science ®Google Scholar
• Overby DR, Clark AF. Animal Models of Glucocorticoid-Induced Glaucoma. Exp Eye Res. 2015;141:15–22. doi:10.1016/j.exer.2015.06.002
   PubMed Web of Science ®Google Scholar
• Tektas OY, Lütjen-Drecoll E. Structural changes of the trabecular meshwork in different kinds of glaucoma. Exp Eye Res. 2009;88(4):769–775. doi:10.1016/j.exer.2008.11.025
   PubMed Web of Science ®Google Scholar
• el-Shabrawi Y, Eckhardt M, Berghold A, et al. Synthesis pattern of matrix metalloproteinases (MMPs) and inhibitors (TIMPs) in human explant organ cultures after treatment with latanoprost and dexamethasone. Eye Lond Engl. 2000;14(Pt 3A):375–383. doi:10.1038/eye.2000.92
   PubMedGoogle Scholar
• Mohd Nasir NA, Agarwal R, Krasilnikova A, Abdul Kadir SH S, Iezhitsa I. Effect of dexamethasone on the expression of MMPs, adenosine A1 receptors and NFKB by human trabecular meshwork cells. J Basic Clin Physiol Pharmacol. 2020;31(6). doi:10.1515/jbcpp-2019-0373
   PubMedGoogle Scholar
• Mohd Nasir NA, Agarwal R, Krasilnikova A, Abdul Kadir SH S, Iezhitsa I. Effect of trans-resveratrol on dexamethasone-induced changes in the expression of MMPs by human trabecular meshwork cells: involvement of adenosine A1 receptors and NFkB. Eur J Pharmacol. 2020;887:173431. doi:10.1016/j.ejphar.2020.173431
   PubMed Web of Science ®Google Scholar
• Rohen JW, Linnér E, Witmer R. Electron microscopic studies on the trabecular meshwork in two cases of corticosteroid-glaucoma. Exp Eye Res. 1973;17(1):19–31. doi:10.1016/0014-4835(73)90164-4
   PubMed Web of Science ®Google Scholar
• Overby DR, Bertrand J, Tektas OY, et al. Ultrastructural Changes Associated With Dexamethasone-Induced Ocular Hypertension in Mice. Invest Ophthalmol Vis Sci. 2014;55(8):4922–4933. doi:10.1167/iovs.14-14429
   PubMed Web of Science ®Google Scholar
• Dibas A, Clark AF, Yorio T. Increased expression of glucocorticoid receptor B induces a novel transforming growth factor beta-2 isoform in trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2016;57(12):86.
   Web of Science ®Google Scholar
• Gerometta R, Kumar S, Shah S, Alvarez L, Candia O, Danias J. Reduction of Steroid-Induced Intraocular Pressure Elevation in Sheep by Tissue Plasminogen Activator. Invest Ophthalmol Vis Sci. 2013;54(13):7903–7909. doi:10.1167/iovs.13-12801
   PubMed Web of Science ®Google Scholar
• Kumar S, Shah S, Tang HM, Smith M, Borrás T, Danias J. Tissue plasminogen activator in trabecular meshwork attenuates steroid induced outflow resistance in mice. PLoS One. 2013;8(8):e72447. doi:10.1371/journal.pone.0072447
   PubMed Web of Science ®Google Scholar
• Gindina S, Barron AO, Hu Y, Dimopoulos A, Danias J. Tissue plasminogen activator rescues steroid-induced outflow facility reduction via non-enzymatic action. Mol Vis. 2021;27:691–705.
   PubMed Web of Science ®Google Scholar
• Underwood JL, Murphy CG, Chen J, et al. Glucocorticoids regulate transendothelial fluid flow resistance and formation of intercellular junctions. Am J Physiol. 1999;277(2):C330–342. doi:10.1152/ajpcell.1999.277.2.C330
   PubMedGoogle Scholar
• Vahabikashi A, Park CY, Perkumas K, et al. Probe Sensitivity to Cortical versus Intracellular Cytoskeletal Network Stiffness. Biophys J. 2019;116(3):518–529. doi:10.1016/j.bpj.2018.12.021
   PubMed Web of Science ®Google Scholar
• Overby DR, Zhou EH, Vargas-Pinto R, et al. Altered mechanobiology of Schlemm’s canal endothelial cells in glaucoma. Proc Natl Acad Sci U S A. 2014;111(38):13876–13881. doi:10.1073/pnas.1410602111
   PubMed Web of Science ®Google Scholar
• Rosenquist R, Epstein D, Melamed S, Johnson M, Grant WM. Outflow resistance of enucleated human eyes at two different perfusion pressures and different extents of trabeculotomy. Curr Eye Res. 1989;8(12):1233–1240. doi:10.3109/02713688909013902
   PubMed Web of Science ®Google Scholar
• Gonzalez JM, Ko MK, Hong YK, Weigert R, Tan JCH. Deep tissue analysis of distal aqueous drainage structures and contractile features. Sci Rep. 2017;7(1):17071. doi:10.1038/s41598-017-16897-y
   PubMedGoogle Scholar
• McDonnell F, Dismuke WM, Overby DR, Stamer WD. Pharmacological regulation of outflow resistance distal to Schlemm’s canal. Am J Physiol Cell Physiol. 2018;315(1):C44–C51. doi:10.1152/ajpcell.00024.2018
   PubMed Web of Science ®Google Scholar
• Roy Chowdhury U, Fautsch MP. Isolation and Culture of Vascular Distal Outflow Pathway (VDOP) Cells From Human Donor Eyes. Curr Protoc. 2022;2(8):e528. doi:10.1002/cpz1.528
   PubMedGoogle Scholar
• Abtahi M, Rudnisky CJ, Nazarali S, Damji KF. Incidence of steroid response in microinvasive glaucoma surgery with trabecular microbypass stent and ab interno trabeculectomy. Can J Ophthalmol. 2022;57(3):167–174. doi:10.1016/j.jcjo.2021.04.008
   PubMed Web of Science ®Google Scholar
• Bojikian KD, Nobrega P, Roldan A, Forrest SL, Tsukikawa M, Chen PP. Incidence of and Risk Factors for Steroid Response After Cataract Surgery in Patients With and Without Glaucoma. J Glaucoma. 2021;30(4):e159–e163. doi:10.1097/IJG.0000000000001785
   PubMed Web of Science ®Google Scholar
• Rajendrababu S, Pallamparthy S, Arunachalam A, et al. Incidence and risk factors for postoperative intraocular pressure response to topical prednisolone eye drops in patients undergoing phacoemulsification. Int Ophthalmol. 2021;41(12):3999–4007. doi:10.1007/s10792-021-01972-1
   PubMed Web of Science ®Google Scholar
• Badrinarayanan L, Rishi P, George R, Isaac N, Rishi E. for the Sankara Nethralaya Vitreo-Retinal group (SNVR). Incidence, Risk Factors, Treatment, and Outcome of Ocular Hypertension following Intravitreal Steroid Injections: a Comparative Study. Ophthalmologica. 2022;245(5):431–438. doi:10.1159/000522504
   PubMed Web of Science ®Google Scholar
• Krag S, Larsen D, Albertsen BK, Glerup M. Risk of ocular hypertension in children treated with systemic glucocorticoid. Acta Ophthalmol (Copenh). 2021;99(8):e1430–e1434. doi:10.1111/aos.14820
   Web of Science ®Google Scholar
• Kiddee W, Trope GE, Sheng L, et al. Intraocular Pressure Monitoring Post Intravitreal Steroids: a Systematic Review. Surv Ophthalmol. 2013;58(4):291–310. doi:10.1016/j.survophthal.2012.08.003
   PubMed Web of Science ®Google Scholar
• Mataftsi A, Dabbagh A, Moore W, Nischal KK. Evaluation of whether intracameral dexamethasone predisposes to glaucoma after pediatric cataract surgery. J Cataract Refract Surg. 2012;38(10):1719. doi:10.1016/j.jcrs.2012.05.034
   PubMed Web of Science ®Google Scholar
• Chang DT, Herceg MC, Bilonick RA, Camejo L, Schuman JS, Noecker RJ. Intracameral dexamethasone reduces inflammation on the first postoperative day after cataract surgery in eyes with and without glaucoma. Clin Ophthalmol Auckl NZ. 2009;3:345–355.
   PubMedGoogle Scholar
• Yamashita T, Kodama Y, Tanaka M, Yamakiri K, Kawano Y, Sakamoto T. Steroid-induced glaucoma in children with acute lymphoblastic leukemia: a possible complication. J Glaucoma. 2010;19(3):188–190. doi:10.1097/IJG.0b013e3181af321d
   PubMed Web of Science ®Google Scholar
• Chan CKM, Mohamed S, Lee VYW, Lai TYY, Shanmugam MP, Lam DSC. Intravitreal dexamethasone for diabetic macular edema: a pilot study. Ophthalmic Surg Lasers Imaging off J Int Soc Imaging Eye. 2010;41(1):26–30. doi:10.3928/15428877-20091230-05
   PubMedGoogle Scholar
• Lebrize S, Arnould L, Bourredjem A, et al. Intraocular Pressure Changes After Intravitreal Fluocinolone Acetonide Implant: results from Four European Countries. Ophthalmol Ther. 2022;11(3):1217–1229. doi:10.1007/s40123-022-00504-z
   PubMed Web of Science ®Google Scholar
• Alsaadi M, Osuagwu U, Almubrad T. Effects of inhaled fluticasone on intraocular pressure and central corneal thickness in asthmatic children without a family history of glaucoma. Middle East Afr J Ophthalmol. 2012;19(3):314–319. doi:10.4103/0974-9233.97936
   PubMedGoogle Scholar
• Acar M, Gedizlioglu M, Koskderelioglu A, Ozturk F, Kilinc S, Talay N. Effect of High-Dose Intravenous Methyl-prednisolone Treatment on Intraocular Pressure in Multiple Sclerosis Patients with Relapse. Eur Neurol. 2012;68(1):20–22. doi:10.1159/000337615
   PubMed Web of Science ®Google Scholar
• Tripathi RC, Kirschner BS, Kipp M, et al. Corticosteroid treatment for inflammatory bowel disease in pediatric patients increases intraocular pressure. Gastroenterology. 1992;102(6):1957–1961. doi:10.1016/0016-5085(92)90319-T
   PubMed Web of Science ®Google Scholar
• Ding X, Li J, Hu X, Yu S, Pan J, Tang S. PROSPECTIVE STUDY OF INTRAVITREAL TRIAMCINOLONE ACETONIDE VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION. RETINA. 2011;31(5):838. doi:10.1097/IAE.0b013e3181f4420d
   PubMed Web of Science ®Google Scholar
• Chang YC, Wu WC. Elevation of Intraocular Pressure After Intravitreal Injection of Triamcinolone Acetonide in Taiwanese Patients. Kaohsiung J Med Sci. 2008;24(2):72–77. doi:10.1016/S1607-551X(08)70100-1
   PubMed Web of Science ®Google Scholar
• Chuang LH, Yeung L, Wang NK, Chen HSL, Ku WC, Lai CC. Secondary Ocular Hypertension After Intravitreal Injection with 2 mg or 4 mg of Triamcinolone in Retinal Vein Occlusion. J Ocul Pharmacol Ther. 2010;26(4):325–328. doi:10.1089/jop.2010.0039
   PubMed Web of Science ®Google Scholar
• Jain S, Thompson JR, Foot B, Tatham A, Eke T. Severe intraocular pressure rise following intravitreal triamcinolone: a national survey to estimate incidence and describe case profiles. Eye. 2014;28(4):399–401. doi:10.1038/eye.2013.306
   PubMed Web of Science ®Google Scholar
• Chew EY, Glassman AR, Beck RW, et al. Ocular side effects associated with peribulbar injections of triamcinolone acetonide for diabetic macular edema. Retina (Philadelphia, Pa). 2011;31(2):284–289. doi:10.1097/IAE.0b013e3181f049a8
   PubMed Web of Science ®Google Scholar
• Hirooka K, Shiraga F, Tanaka S, Baba T, Mandai H. Risk Factors for Elevated Intraocular Pressure After Trans-Tenon Retrobulbar Injections of Triamcinolone. Jpn J Ophthalmol. 2006;50(3):235–238. doi:10.1007/s10384-005-0306-9
   PubMed Web of Science ®Google Scholar
• Kawaji T, Takano A, Inomata Y, et al. Trans-Tenon’s retrobulbar triamcinolone acetonide injection for macular oedema related to branch retinal vein occlusion. Br J Ophthalmol. 2008;92(1):81–83. doi:10.1136/bjo.2007.124578
   PubMed Web of Science ®Google Scholar
• Spiers F. Topical Steroids and Intraocular Pressure. Acta Ophthalmol (Copenh). 1965;43(5):735–745. doi:10.1111/j.1755-3768.1965.tb00346.x
   PubMedGoogle Scholar
• Yamamoto Y, Komatsu T, Koura Y, Nishino K, Fukushima A, Ueno H. Intraocular pressure elevation after intravitreal or posterior sub-Tenon triamcinolone acetonide injection. Can J Ophthalmol. 2008;43(1):42–47. doi:10.3129/i07-186
   PubMed Web of Science ®Google Scholar
• Lafranco Dafflon M, Tran VT, Guex-Crosier Y, Herbort CP. Posterior sub-Tenon’s steroid injections for the treatment of posterior ocular inflammation: indications, efficacy and side effects. Graefes Arch Clin Exp Ophthalmol. 1999;237(4):289–295. doi:10.1007/s004170050235
   PubMed Web of Science ®Google Scholar
• Yalcinsoy KO, Ozdal PC, Sen E, Elgin U. Intraocular Pressure Elevation After Posterior Subtenon Triamcinolone Acetonide Injection in Pediatric Non-Infectious Uveitis. Beyoglu Eye J. 2022;7(4):298–303. doi:10.14744/bej.2022.97752
   PubMedGoogle Scholar
• Ateeq A, Majid S, Ahmed Memon N, Hayat N, Qadeem Somroo A, Fattah Memon A. Suprachoroidal injection of triamcinolone acetonide for management of resistant diabetic macular edema (SCTA): original article. J Pak Med Assoc. 2023;73(2):239–244. doi:10.47391/JPMA.2239
   PubMed Web of Science ®Google Scholar
• Marashi A, Zazo A. Suprachoroidal injection of triamcinolone acetonide using a custom-made needle to treat diabetic macular edema post pars plana vitrectomy: a case series. J Int Med Res. 2022;50(4):03000605221089807. doi:10.1177/03000605221089807
   PubMed Web of Science ®Google Scholar
• Yeh S, Khurana RN, Shah M, et al. Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial. Ophthalmology. 2020;127(7):948–955. doi:10.1016/j.ophtha.2020.01.006
   PubMed Web of Science ®Google Scholar
• Cantrill HL, Palmberg PF, Zink HA, Waltman SR, Podos SM, Becker B. Comparison of in Vitro Potency of Corticosteroids with Ability to Raise Intraocular Pressure. Am J Ophthalmol. 1975;79(6):1012–1017. doi:10.1016/0002-9394(75)90687-X
   PubMed Web of Science ®Google Scholar
• Kao BW, Fong CW, Yu Y, Ying GS, Gedde SJ, Han Y. Surgical Outcomes of Ahmed Glaucoma Valve Implantation with Postoperative Use of Prednisolone Acetate versus Difluprednate. Ophthalmol Glaucoma. 2022;5(5):468–475. doi:10.1016/j.ogla.2022.03.003
   PubMedGoogle Scholar
• Tripathi RC, Parapuram SK, Tripathi BJ, Zhong Y, Chalam KV. Corticosteroids and Glaucoma Risk. Drugs Aging. 1999;15(6):439–450. doi:10.2165/00002512-199915060-00004
   PubMed Web of Science ®Google Scholar
• Korenfeld M, Nichols KK, Goldberg D, et al. Safety of KPI-121 Ophthalmic Suspension 0.25% in Patients With Dry Eye Disease: a Pooled Analysis of 4 Multicenter, Randomized, Vehicle-Controlled Studies. Cornea. 2021;40(5):564. doi:10.1097/ICO.0000000000002452
   PubMed Web of Science ®Google Scholar
• Sheppard JD, Comstock TL, Cavet ME. Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure. Adv Ther. 2016;33(4):532–552. doi:10.1007/s12325-016-0315-8
   PubMed Web of Science ®Google Scholar
• Price MO, Feng MT, Scanameo A, Price FWJ. Loteprednol Etabonate 0.5% Gel Vs. Prednisolone Acetate 1% Solution After Descemet Membrane Endothelial Keratoplasty: prospective Randomized Trial. Cornea. 2015;34(8):853. doi:10.1097/ICO.0000000000000475
   PubMed Web of Science ®Google Scholar
• Raj A, Salvador-Culla B, Anwar H, Sykakis E, Figueiredo MS, Figueiredo FC. Long-term Outcomes on de novo Ocular Hypertensive Response to Topical Corticosteroids After Corneal Transplantation. Cornea. 2020;39(1):45. doi:10.1097/ICO.0000000000002142
   PubMed Web of Science ®Google Scholar
• Chen YH, Gepstein R, Sharief L, et al. Outcome and risk of ocular complications of managing children with chronic anterior uveitis with topical rimexolone 1%. Int Ophthalmol. 2020;40(5):1061–1068. doi:10.1007/s10792-020-01358-9
   PubMed Web of Science ®Google Scholar
• Armaly MF. Effect of Corticosteroids on Intraocular Pressure and Fluid Dynamics: II.he Effect of Dexamethasone in the Glaucomatous Eye. Arch Ophthalmol. 1963;70(4):492–499. doi:10.1001/archopht.1963.00960050494011
   PubMedGoogle Scholar
• Becker B. Intraocular pressure response to topical corticosteroids. Invest Ophthalmol. 1965;4:198–205.
   PubMedGoogle Scholar
• Feroze KB, Zeppieri M, Khazaeni L. Steroid Induced Glaucoma. StatPearls Publishing; 2023. http://www.ncbi.nlm.nih.gov/books/NBK430903/. Accessed March 25, 2023.
   Google Scholar
• Choi W, Bae HW, Choi EY, et al. Age as a risk factor for steroid-induced ocular hypertension in the non-paediatric population. Br J Ophthalmol. 2020;104(10):1423–1429. doi:10.1136/bjophthalmol-2019-314559
   PubMed Web of Science ®Google Scholar
• Malclès A, Dot C, Voirin N, et al. SAFETY OF INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX): the SAFODEX study. Incidence and Risk Factors of Ocular Hypertension. RETINA. 2017;37(7):1352. doi:10.1097/IAE.0000000000001369
   PubMed Web of Science ®Google Scholar
• Maier AKB, Pilger D, Gundlach E, Winterhalter S, Torun N. Long-term Results of Intraocular Pressure Elevation and Post-DMEK Glaucoma After Descemet Membrane Endothelial Keratoplasty. Cornea. 2021;40(1):26. doi:10.1097/ICO.0000000000002363
   PubMed Web of Science ®Google Scholar
• Armaly MF. Inheritance of Dexamethasone Hypertension and Glaucoma. Arch Ophthalmol. 1967;77(6):747–751. doi:10.1001/archopht.1967.00980020749006
   PubMedGoogle Scholar
• Bartlett JD, Woolley TW, Adams CM. Identification of High Intraocular Pressure Responders to Topical Ophthalmic Corticosteroids. J Ocul Pharmacol Ther. 1993;9(1):35–45. doi:10.1089/jop.1993.9.35
   Google Scholar
• Mitchell P, Cumming RG, Mackey DA. Inhaled corticosteroids, family history, and risk of glaucoma. Ophthalmology. 1999;106(12):2301–2306. doi:10.1016/S0161-6420(99)90530-4
   PubMed Web of Science ®Google Scholar
• Razeghinejad MR, Katz LJ. Steroid-Induced Iatrogenic Glaucoma. Ophthalmic Res. 2012;47(2):66–80. doi:10.1159/000328630
   PubMed Web of Science ®Google Scholar
• Jones RI, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol. 2006;17(2):163. doi:10.1097/01.icu.0000193079.55240.18
   PubMed Web of Science ®Google Scholar
• Friedman DS, Holbrook JT, Ansari H, et al. Risk of Elevated Intraocular Pressure and Glaucoma in Patients with Uveitis: results of the Multicenter Uveitis Steroid Treatment Trial. Ophthalmology. 2013;120(8):1571–1579. doi:10.1016/j.ophtha.2013.01.025
   PubMed Web of Science ®Google Scholar
• Biedner BZ, David R, Grudsky A, Sachs U. Intraocular pressure response to corticosteroids in children. Br J Ophthalmol. 1980;64(6):430–431. doi:10.1136/bjo.64.6.430
   PubMed Web of Science ®Google Scholar
• Hutcheson KA. Steroid-induced glaucoma in an infant. J Am Assoc Pediatr Ophthalmol Strabismus. 2007;11(5):522–523. doi:10.1016/j.jaapos.2007.03.008
   Google Scholar
• Lam DS, Fan DS, Ng JS, Yu CB, Wong CY, Cheung AY. Ocular hypertensive and anti-inflammatory responses to different dosages of topical dexamethasone in children: a randomized trial. Clin Experiment Ophthalmol. 2005;33(3):252–258. doi:10.1111/j.1442-9071.2005.01022.x
   PubMed Web of Science ®Google Scholar
• Gaston H, Absolon MJ, Thurtle OA, Sattar MA. Steroid responsiveness in connective tissue diseases. Br J Ophthalmol. 1983;67(7):487–490. doi:10.1136/bjo.67.7.487
   PubMed Web of Science ®Google Scholar
• Podos SM, Becker B, Ross Morton W. High Myopia And Primary Open-Angle Glaucoma. Am J Ophthalmol. 1966;62(6):1039–1043. doi:10.1016/0002-9394(66)92551-7
   Web of Science ®Google Scholar
• Becker B, Bresnick G, Chevrette L, Kolker AE, Oaks MC, Cibis A. Intraocular Pressure and Its Response to Topical Corticosteroids in Diabetes. Arch Ophthalmol. 1966;76(4):477–483. doi:10.1001/archopht.1966.03850010479003
   PubMedGoogle Scholar
• Hámor A, Markó R, Rák T, Csutak A. A szteroidterápia hatása az intraocularis nyomásra. Orv Hetil. 2022;163(34):1345–1352. doi:10.1556/650.2022.32548
   PubMedGoogle Scholar
• Dibas A, Yorio T. Glucocorticoid Therapy and ocular hypertension. Eur J Pharmacol. 2016;787:57–71. doi:10.1016/j.ejphar.2016.06.018
   PubMed Web of Science ®Google Scholar
• Agrahari V, Mandal A, Agrahari V, et al. A COMPREHENSIVE INSIGHT ON OCULAR PHARMACOKINETICS. Drug Deliv Transl Res. 2016;6(6):735–754. doi:10.1007/s13346-016-0339-2
   PubMed Web of Science ®Google Scholar
• Benedetti MS, Whomsley R, Poggesi I, et al. Drug metabolism and pharmacokinetics. Drug Metab Rev. 2009;41(3):344–390. doi:10.1080/10837450902891295
   PubMed Web of Science ®Google Scholar
• Razeghinejad MR, Myers JS, Katz LJ. Iatrogenic Glaucoma Secondary to Medications. Am J Med. 2011;124(1):20–25. doi:10.1016/j.amjmed.2010.08.011
   PubMed Web of Science ®Google Scholar
• Sihota R, Konkal VL, Dada T, Agarwal HC, Singh R. Prospective, long-term evaluation of steroid-induced glaucoma. Eye. 2008;22(1):26–30. doi:10.1038/sj.eye.6702474
   PubMed Web of Science ®Google Scholar
• Phulke S, Kaushik S, Kaur S. Steroid-induced Glaucoma: an Avoidable Irreversible Blindness. J Curr Glaucoma Pract. 2017;11(2):67–72. doi:10.5005/jp-journals-l0028-1226
   PubMedGoogle Scholar
• Cunningham MA, Edelman JL, Kaushal S. Intravitreal Steroids for Macular Edema: the Past, the Present, and the Future. Surv Ophthalmol. 2008;53(2):139–149. doi:10.1016/j.survophthal.2007.12.005
   PubMed Web of Science ®Google Scholar
• Muftuoglu IK, Tokuc EO, Sümer F, Karabas VL. Evaluation of retinal inflammatory biomarkers after intravitreal steroid implant and Ranibizumab injection in diabetic macular edema. Eur J Ophthalmol. 2022;32(3):1627–1635. doi:10.1177/11206721211029465
   PubMed Web of Science ®Google Scholar
• Graham RO, Peyman GA. Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis. Arch Ophthalmol Chic IL 1960. 1974;92(2):149–154. doi:10.1001/archopht.1974.01010010155016
   PubMedGoogle Scholar
• Mansoor S, Kuppermann BD, Kenney MC. Intraocular sustained-release delivery systems for triamcinolone acetonide. Pharm Res. 2009;26(4):770–784. doi:10.1007/s11095-008-9812-z
   PubMed Web of Science ®Google Scholar
• Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB, Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110(4):681–686. doi:10.1016/S0161-6420(02)01969-3
   PubMed Web of Science ®Google Scholar
• Chin HS, Park TS, Moon YS, Oh JH. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina (Philadelphia, Pa). 2005;25(5):556–560. doi:10.1097/00006982-200507000-00002
   PubMed Web of Science ®Google Scholar
• Ansari EA, Ali N. Intraocular Pressure Following Intravitreal Injection of Triamcinolone Acetonide. Open Ophthalmol J. 2008;2:119–122. doi:10.2174/1874364100802010119
   PubMedGoogle Scholar
• Gaballa SA, Kompella UB, Elgarhy O, et al. Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives. Drug Deliv Transl Res. 2021;11(3):866–893. doi:10.1007/s13346-020-00843-z
   PubMed Web of Science ®Google Scholar
• Rajesh B, Zarranz-Ventura J, Fung AT, et al. Safety of 6000 intravitreal dexamethasone implants. Br J Ophthalmol. 2020;104(1):39–46. doi:10.1136/bjophthalmol-2019-313991
   PubMed Web of Science ®Google Scholar
• Muya L, Kansara V, Cavet ME, Ciulla T. Suprachoroidal Injection of Triamcinolone Acetonide Suspension: ocular Pharmacokinetics and Distribution in Rabbits Demonstrates High and Durable Levels in the Chorioretina. J Ocul Pharmacol Ther. 2022;38(6):459–467. doi:10.1089/jop.2021.0090
   PubMed Web of Science ®Google Scholar
• Fung S, Syed YY. Suprachoroidal Space Triamcinolone Acetonide: a Review in Uveitic Macular Edema. Drugs. 2022;82(13):1403–1410. doi:10.1007/s40265-022-01763-7
   PubMed Web of Science ®Google Scholar
• Price KW, Albini TA, Yeh S. Suprachoroidal Injection of Triamcinolone— review of a Novel Treatment for Macular Edema Caused by Noninfectious Uveitis. US Ophthalmic Rev. 2020;13(2):76–79. doi:10.17925/usor.2020.13.2.76
   PubMedGoogle Scholar
• Tabl AA, Elsayed MA, Tabl MA. Suprachoroidal triamcinolone acetonide injection: a novel therapy for serous retinal detachment due to Vogt-Koyanagi Harada disease. Eur J Ophthalmol. 2022;32(6):3482–3488. doi:10.1177/11206721221085420
   PubMed Web of Science ®Google Scholar
• Weijtens O, Schoemaker RC, Lentjes EGWM, Fphtm R, Cohen AF, van MJC. Dexamethasone concentration in the subretinal fluid after a subconjunctival injection, a peribulbar injection, or an oral dose. Ophthalmology. 2000;107(10):1932–1938. doi:10.1016/S0161-6420(00)00344-4
   PubMed Web of Science ®Google Scholar
• Conrad JM, Robinson JR. Mechanisms of anterior segment absorption of pilocarpine following subconjunctival injection in albino rabbits. J Pharm Sci. 1980;69(8):875–884. doi:10.1002/jps.2600690806
   PubMed Web of Science ®Google Scholar
• McGhee CNJ, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf. 2002;25(1):33–55. doi:10.2165/00002018-200225010-00004
   PubMed Web of Science ®Google Scholar
• Garbe E, LeLorier J, Boivin JF, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA. 1997;277(9):722–727.
   PubMed Web of Science ®Google Scholar
• Macris N. Glucocorticoid use and risks of ocular hypertension and glaucoma. JAMA. 1997;277(24):1929. doi:10.1001/jama.277.24.1929b
   PubMedGoogle Scholar
• Nath T, Roy SS, Kumar H, Agrawal R, Kumar S, Satsangi SK. Prevalence of Steroid-Induced Cataract and Glaucoma in Chronic Obstructive Pulmonary Disease Patients Attending a Tertiary Care Center in India. Asia-Pac J Ophthalmol. 2017;6(1):28. doi:10.22608/APO.201616
   PubMed Web of Science ®Google Scholar
• Marcus MW, Müskens RPHM, Ramdas WD, et al. Corticosteroids and Open-Angle Glaucoma in the Elderly. Drugs Aging. 2012;29(12):963–970. doi:10.1007/s40266-012-0029-9
   PubMed Web of Science ®Google Scholar
• Duh MS, Walker AM, Lindmark B, Laties AM. Association between intraocular pressure and budesonide inhalation therapy in asthmatic patients. Ann Allergy Asthma Immunol. 2000;85(5):356–361. doi:10.1016/S1081-1206(10)62545-8
   PubMed Web of Science ®Google Scholar
• Johnson LN, Soni CR, Johnson MAJ, Madsen RW. Short-term use of inhaled and intranasal corticosteroids is not associated with glaucoma progression on optical coherence tomography. Eur J Ophthalmol. 2012;22(5):695–700. doi:10.5301/ejo.5000141
   PubMed Web of Science ®Google Scholar
• Ahmadi N, Snidvongs K, Kalish L, et al. Intranasal corticosteroids do not affect intraocular pressure or lens opacity: a systematic review of controlled trials. Rhinol J. 2015;53(4):290–302. doi:10.4193/Rhino15.020
   PubMed Web of Science ®Google Scholar
• Gonzalez AV, Li G, Suissa S, Ernst P. Risk of glaucoma in elderly patients treated with inhaled corticosteroids for chronic airflow obstruction. Pulm Pharmacol Ther. 2010;23(2):65–70. doi:10.1016/j.pupt.2009.10.014
   PubMed Web of Science ®Google Scholar
• Ishii M, Horita N, Takeuchi M, et al. Inhaled Corticosteroid and Secondary Glaucoma: a Meta-analysis of 18 Studies. Allergy Asthma Immunol Res. 2021;13(3):435–449. doi:10.4168/aair.2021.13.3.435
   PubMed Web of Science ®Google Scholar
• Opatowsky I, Feldman RM, Gross R, Feldman ST. Intraocular Pressure Elevation Associated with Inhalation and Nasal Corticosteroids. Ophthalmology. 1995;102(2):177–179. doi:10.1016/S0161-6420(95)31039-1
   PubMed Web of Science ®Google Scholar
• Valenzuela CV, Liu JC, Vila PM, Simon L, Doering M, Lieu JEC. Intranasal Corticosteroids Do Not Lead to Ocular Changes: a Systematic Review and Meta-analysis. Laryngoscope. 2019;129(1):6–12. doi:10.1002/lary.27209
   PubMed Web of Science ®Google Scholar
• Bielory B, Bielory L. Over-The-counter migration of steroid use: impact on the eye. Curr Opin Allergy Clin Immunol. 2014;14(5):471–476. doi:10.1097/ACI.0000000000000099
   PubMed Web of Science ®Google Scholar
• Bernstein HN, Schwartz B. Effects of long-term systemic steroids on ocular pressure and tonographic values. Arch Ophthalmol Chic IL 1960. 1962;68:742–753. doi:10.1001/archopht.1962.00960030746009
   PubMed Web of Science ®Google Scholar
• Chadha V, Cruickshank I, Swingler R, Sanders R. Advanced glaucomatous visual loss and oral steroids. BMJ. 2008;337:a670. doi:10.1136/bmj.a670
   PubMedGoogle Scholar
• Garbe E, LeLorier J, Boivin JF, Suissa S. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet Lond Engl. 1997;350(9083):979–982. doi:10.1016/S0140-6736(97)03392-8
   PubMed Web of Science ®Google Scholar
• Wiendl H, Gold R, Berger T, et al. Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Ther Adv Neurol Disord. 2021;14:17562864211039648. doi:10.1177/17562864211039648
   Web of Science ®Google Scholar
• Garrott HM, Walland MJ. Glaucoma from topical corticosteroids to the eyelids. Clin Experiment Ophthalmol. 2004;32(2):224–226. doi:10.1111/j.1442-9071.2004.00787.x
   PubMed Web of Science ®Google Scholar
• Sahni D, Darley CR, Hawk JLM. Glaucoma induced by periorbital topical steroid use − A rare complication. Clin Exp Dermatol. 2004;29(6):617–619. doi:10.1111/j.1365-2230.2004.01610.x
   PubMed Web of Science ®Google Scholar
• Daniel BS, Orchard D. Ocular side−effects of topical corticosteroids: what a dermatologist needs to know. Australas J Dermatol. 2015;56(3):164–169. doi:10.1111/ajd.12292
   PubMed Web of Science ®Google Scholar
• Takakuwa K, Hamanaka T, Mori K, et al. Atopic Glaucoma: clinical and Pathophysiological Analysis. J Glaucoma. 2015;24(9):662. doi:10.1097/IJG.0000000000000069
   PubMed Web of Science ®Google Scholar
• Haeck IM, Rouwen TJ, Timmer-de Mik L, de Bruin-Weller MS, Bruijnzeel-Koomen CA. Topical corticosteroids in atopic dermatitis and the risk of glaucoma and cataracts. J Am Acad Dermatol. 2011;64(2):275–281. doi:10.1016/j.jaad.2010.01.035
   PubMed Web of Science ®Google Scholar
• Huschle OK, Jonas JB, Koniszewski G, Buchfelder M, Fahlbusch R. Glaucoma in central hypothalamic-hypophyseal Cushing syndrome. Fortschritte Ophthalmol Z Dtsch Ophthalmol Ges. 1990;87(5):453–456.
   PubMedGoogle Scholar
• Virevialle C, Brasnu E, Fior R, Baudouin C. Open-angle glaucoma secondary to Cushing syndrome related to an adrenal adenoma: case report. J Fr Ophtalmol. 2014;37(10):e169. doi:10.1016/j.jfo.2014.01.018
   PubMed Web of Science ®Google Scholar
• Griffin S, Boyce T, Edmunds B, Hills W, Grafe M, Tehrani S. Endogenous hypercortisolism inducing reversible ocular hypertension. Am J Ophthalmol Case Rep. 2019;16:100573. doi:10.1016/j.ajoc.2019.100573
   PubMedGoogle Scholar
• Habib SN, Lin Z, Puvanachandra N. Ocular hypertension secondary to high endogenous steroid load in Cushing’s disease. BMJ Case Rep. 2019;12(1):bcr-2018–226738. doi:10.1136/bcr-2018-226738
   Google Scholar
• Ma Y, Chen Z, Ma Z, et al. Increased Risk of Ocular Hypertension in Patients With Cushing’s Disease. J Glaucoma. 2022;31(12):941. doi:10.1097/IJG.0000000000002113
   PubMed Web of Science ®Google Scholar
• Horan T, Salim S Characteristics and Management of Steroid-Induced Glaucoma. American Academy of Ophthalmology; 2021. Available from: https://www.aao.org/eyenet/article/management-of-steroid-induced-glaucoma. Accessed August 30, 2023.
   Google Scholar
• Weinreb RN, Polansky JR, Kramer SG, Baxter JD. Acute effects of dexamethasone on intraocular pressure in glaucoma. Invest Ophthalmol Vis Sci. 1985;26(2):170–175.
   PubMed Web of Science ®Google Scholar
• Agrawal S, Agrawal J, Agrawal TP. Management of intractable glaucoma following intravitreal triamcinolone acetonide. Am J Ophthalmol. 2005;139(3):575–576. doi:10.1016/j.ajo.2004.10.025
   PubMed Web of Science ®Google Scholar
• Rezkallah A, Mathis T, Denis P, Kodjikian L. XEN Gel Stent to Treat Intraocular Hypertension After Dexamethasone-Implant Intravitreal Injections: 5 Cases. J Glaucoma. 2019;28(1):e5. doi:10.1097/IJG.0000000000001092
   PubMed Web of Science ®Google Scholar
• Steroid-Induced Glaucoma - EyeWiki. EyeWiki; 2023. Available from: https://eyewiki.aao.org/Steroid-Induced_Glaucoma. Accessed May 27, 2023.
   Google Scholar
• Zhou Y, Pruet CM, Fang C, Khanna CL. Selective laser trabeculoplasty in steroid-induced and uveitic glaucoma. Can J Ophthalmol. 2022;57(4):277–283. doi:10.1016/j.jcjo.2021.05.006
   PubMed Web of Science ®Google Scholar
• Davidson M, Berkowitz E, Roberts H, Wanas A, Myerscough J. Selective Laser Trabeculoplasty for Steroid-Induced Ocular Hypertension following Endothelial Keratoplasty. Curr Eye Res. 2022;47(10):1362–1365. doi:10.1080/02713683.2022.2088800
   PubMed Web of Science ®Google Scholar
• AlObaida I, Al Owaifeer AM, Alotaibi H, Alsafi A, Ali Aljasim L. Outcomes of selective laser trabeculoplasty in corticosteroid-induced ocular hypertension and glaucoma. Eur J Ophthalmol. 2022;32(3):1525–1529. doi:10.1177/11206721211023310
   PubMed Web of Science ®Google Scholar
• Xiao J, Zhao C, Liang A, Zhang M, Cheng G. Efficacy and Safety of High-Energy Selective Laser Trabeculoplasty for Steroid-Induced Glaucoma in Patients with Quiescent Uveitis. Ocul Immunol Inflamm. 2021;29(4):766–770. doi:10.1080/09273948.2019.1687730
   PubMed Web of Science ®Google Scholar
• Goñi FJ, Stalmans I, Denis P, et al. Elevated Intraocular Pressure After Intravitreal Steroid Injection in Diabetic Macular Edema: monitoring and Management. Ophthalmol Ther. 2016;5(1):47–61. doi:10.1007/s40123-016-0052-8
   PubMedGoogle Scholar
• Hu Y, Barron AO, Gindina S, et al. Investigations on the Role of the Fibrinolytic Pathway on Outflow Facility Regulation. Invest Ophthalmol Vis Sci. 2019;60(5):1571–1580. doi:10.1167/iovs.18-25698
   PubMed Web of Science ®Google Scholar
• Gindina S, Hu Y, Barron AO, Qureshi Z, Danias J. Tissue plasminogen activator attenuates outflow facility reduction in mouse model of juvenile open angle glaucoma. Exp Eye Res. 2020;199:108179. doi:10.1016/j.exer.2020.108179
   PubMed Web of Science ®Google Scholar
• Gerometta R, Spiga MG, Borrás T, Candia OA. Treatment of sheep steroid-induced ocular hypertension with a glucocorticoid-inducible MMP1 gene therapy virus. Invest Ophthalmol Vis Sci. 2010;51(6):3042–3048. doi:10.1167/iovs.09-4920
   PubMed Web of Science ®Google Scholar